F029 DataDerm Discoveries: How Registry Data Are Powering Real-World Research, AI Applications, and Inspiring Your Next Study
DESCRIPTION
The AAD’s clinical data registry, DataDerm, enables real-world research that advances understanding of dermatologic disease, treatment patterns, and patient populations, while also supporting emerging analytic approaches, including artificial intelligence (AI). This session will highlight the evolution of DataDerm, review the scope and structure of data available within DataDerm and examine how these data have been used to generate clinically relevant research findings and specialty-level insights.
Participants will hear from researchers who have leveraged DataDerm data to evaluate disease characteristics, treatment patterns, and variation in care. The session will also outline considerations for using registry data to explore research questions and improve patient care.
LEARNING OBJECTIVES
Identify the types of clinical, treatment, and patient data available within the DataDerm registry that support real-world research.
Describe how registry data have been used to generate real-world evidence and specialty insights related to dermatologic disease and treatment patterns.
Apply registry data concepts to develop research question
DIRECTOR
Steven Daniel Daveluy, MD, FAAD
SPEAKERS
Nicholas David Gulati, MD, PhD, FAAD
Toni Kaye
Sylvia L. Parra, MD, FAAD
DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Nicholas David Gulati, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Toni Kaye
No financial relationships exist with ineligible companies.
Sylvia L. Parra, MD, FAAD
No financial relationships exist with ineligible companies.